What is CHD Bioscience?
Based in Fort Collins, Colorado, CHD Bioscience operates at the intersection of biotechnology and public health. The company is dedicated to the discovery, development, and commercialization of proprietary disinfectant solutions engineered to neutralize a broad spectrum of lethal pathogens. By targeting the root causes of infectious disease transmission in both human and veterinary clinical environments, CHD Bioscience aims to establish a new standard for sanitation and infection prevention. Their market position is defined by a commitment to mitigating the rising prevalence of healthcare-associated infections, a critical challenge for modern medical infrastructure in both industrialized and emerging economies.
How much funding has CHD Bioscience raised?
CHD Bioscience has raised a total of $10.9M across 4 funding rounds:
Private Equity
$3.2M
Private Equity
$1.7M
Private Equity
$3.3M
Private Equity
$2.7M
Private Equity (2014): $3.2M, investors not publicly disclosed
Private Equity (2015): $1.7M, investors not publicly disclosed
Private Equity (2016): $3.3M, investors not publicly disclosed
Private Equity (2017): $2.7M, investors not publicly disclosed
Key Investors in CHD Bioscience
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for CHD Bioscience?
With the recent infusion of capital, CHD Bioscience is well-positioned to accelerate its research and development pipeline and scale its commercial operations. The strategic focus will likely shift toward expanding the regulatory approval footprint for its core disinfectant products and enhancing manufacturing capabilities to meet global demand. As the company transitions into this next phase of enterprise-level growth, the emphasis will remain on clinical validation and the deployment of its pathogen-killing solutions into high-acuity healthcare settings. This strategic roadmap is designed to solidify the company's role as a primary innovator in the global fight against infectious disease, leveraging its recent financing to drive long-term operational sustainability and market penetration.
See full CHD Bioscience company page
